公开(公告)号：US10761087B2

公开(公告)日：2020-09-01

申请号：US16063047

申请日：2016-12-16

Applicant: Link Genomics, Inc. ,  ROHTO Pharmaceutical Co., Ltd.

Inventor： Shinichiro Niwa ,  Dai Ogura ,  Hidemi Mizunuma ,  Yoko Arai ,  Takahiro Kurose ,  Yoshihiro Takai ,  Yoko Mitsuguchi ,  Mariyo Moriya

IPC: G01N33/50 ,  A61K31/436 ,  A61K31/192 ,  A61K31/38 ,  A61K31/404 ,  A61K31/421 ,  A61K31/426 ,  A61K31/47 ,  A61K31/41 ,  A61K45/00 ,  A61P27/02 ,  A61K45/06

Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

公开(公告)号：US20230172969A1

公开(公告)日：2023-06-08

申请号：US17921065

申请日：2021-03-31

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Tatsuya Ando ,  Yoko Mitsuguchi ,  Sachiko Matsumoto ,  Atsuko Nakata

IPC: A61K31/737 ,  A61K9/00 ,  A61K31/23 ,  A61K31/355 ,  A61K31/205 ,  A61K31/198 ,  A61K31/27 ,  A61K47/38 ,  A61K31/4415 ,  A61K31/16 ,  A61P27/04 ,  A61K31/4166 ,  A61K31/704

CPC classification number: A61K31/737 ,  A61K9/0048 ,  A61K31/23 ,  A61K31/355 ,  A61K31/205 ,  A61K31/198 ,  A61K31/27 ,  A61K47/38 ,  A61K31/4415 ,  A61K31/16 ,  A61P27/04 ,  A61K31/4166 ,  A61K31/704

Abstract: The present invention relates to an ophthalmic composition for suppressing eye dryness, comprising at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 30,000 to 50,000 and a salt thereof.

公开(公告)号：US20180364216A1

公开(公告)日：2018-12-20

申请号：US16063047

申请日：2016-12-16

Applicant: Link Genomics, Inc. ,  ROHTO Pharmaceutical Co., Ltd.

Inventor： Shinichiro Niwa ,  Dai Ogura ,  Hidemi Mizunuma ,  Yoko Arai ,  Takahiro Kurose ,  Yoshihiro Takai ,  Yoko Mitsuguchi ,  Mariyo Moriya

IPC: G01N33/50 ,  A61K31/192 ,  A61K31/404 ,  A61K31/38 ,  A61K31/421 ,  A61K31/426 ,  A61K31/436 ,  A61P27/02

Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.